BioWorld MedTech

Sep. 3, 2010

Spine market facing growth challenges, analyst says

Right now it's better to be a smaller, well-capitalized spine company with a broad product line than a larger spine company, according to one analyst who covers the space. (Medical Device Daily) Read More

Study shows Cepheid's test is an 'Xpert' in diagnosing TB

SYNTAX creates common ground for coronary risk assessment

Washington roundup: Alphatec warned after taking back some manufacturing work

Holiday notice

Med-Tech Notes

Deals roundup: Erba buys most of Ivax shares for $15M

MDD's food for med-tech thought

Agreements/contracts: LifeCell to distribute Novadaq's SPY imaging

Courts report: Allergan to pay $600M to settle Botox-related charges

Financings roundup: AHP discloses results of self-tender offer

Restructuring roundup: Angeion restructures board and names two new officers

People in the News

Product Briefs

MDD's Diagnostic Extra

Today's news in brief

BioWorld

BioWorld briefs for Feb. 14, 2025.

European VCs optimistic for med-tech exit opportunities in 2025

BioWorld MedTech

To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Feb. 14, 2025

European VCs bullish on med-tech investments in 2025

BioWorld MedTech

European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...

3D illustration of acute myeloid leukemia cells

Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML

BioWorld

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...